Abstract
Background
An appropriate animal model for malignant melanoma could be a strong tool to develop
biomarkers through analysis of melanomagenesis.
Objective
Development of a novel animal model that spontaneously develops malignant melanoma
with a high percentage.
Methods
We crossed oncogenic RET (RFP–RET)-carrying transgenic mice of line 304/B6 (RET-mice)
with hairless mice (hr/hr) and newly established hairless RFP–RET-transgenic mice
of line 304-hr/hr (HL-RET-mice).
Results
The HL-RET-mice developed hyperpigmented skin and benign melanocytic tumors without
exception. More importantly, 63.8% (46/72) of the benign tumors were transformed to
malignant melanoma in the HL-RET-mice. Mean time until the development of benign melanocytic
tumors (2.4 months; n = 102) in the HL-RET-mice was about half of that in the original RET-mice (4.6 months;
n = 20). Mean life span in the HL-RET-mice (9.7 months; n = 38) was also significantly (p < 0.01) shorter than that in the original RET-mice (10.8 months; n = 20). Since early development of tumors could contribute to shortening of the research
period, HL-RET-mice could be a useful model for analysis of melanomagenesis. We then
found that the expression level of Mps one binder kinase activator-like-2B (Mobkl2b)
in benign tumors was higher than that in malignant melanoma in HL-RET-mice. Expression
level of MOBKL2B in malignant melanoma cell lines was also lower than that in non-malignant
melanocytic cells in mice and humans, suggesting that MOBKL2B could be a novel marker
for malignant melanoma.
Conclusion
We established a novel hairless RET-transgenic mouse line spontaneously developing
cutaneous malignant melanomas from benign melanocytic tumors. This mouse model may
be useful to find new candidates of melanoma-related molecule.
Abbreviations:
RET-mice (RFP–RET carried transgenic mice of line 304/B6), HL-RET-mice (hairless RFP–RET-transgenic mice of line 304-hr/hr), Hprt (hypoxanthine guanine phosphoribosyl transferase), Mobkl2B (Mps one binder kinase activator-like-2-B)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Comparison between familial and non-familial melanoma in France.Arch Dermatol. 1995; 131: 1154-1159
- Characteristics of familial and non-familial melanoma in Australia.Melanoma Res. 1998; 8: 459-464
- Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.J Clin Pathol. 2005; 58: 453-456
- Epidemiology of melanoma.Semin Cutan Med Surg. 2010; 29: 204-209
- Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium.Pigment Cell Res. 1999; 12: 71-80
- Pathways to melanoma development: lessons from the mouse.J Invest Dermatol. 2002; 119: 783-792
- Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.Nature. 1994; 367: 380-383
- Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.Mol Biol Cell. 2000; 11: 93-101
- The GDNF/RET signaling pathway and human diseases.Cytokine Growth Factor Rev. 2001; 12: 361-373
- c-Ret-mediated hearing loss in mice with Hirschsprung disease.Proc Natl Acad Sci USA. 2010; 107: 13051-13056
- Activation of a novel human transforming gene, ret, by DNA rearrangement.Cell. 1985; 42: 581-588
- Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.Antioxid Redox Signal. 2000; 2: 841-849
- Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene.EMBO J. 1991; 10: 3167-3175
- Transgenic mouse model for skin malignant melanoma.Oncogene. 1998; 17: 1885-1888
- c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model.Cancer Res. 2004; 64: 801-806
- Protective effect of hyperpigmented skin on UV-mediated cutaneous cancer development.J Invest Dermatol. 2007; 127: 1244-1249
- A novel mouse model for de novo melanoma.Cancer Res. 2010; 70: 24-29
- Resistance to anti-angiogenic therapy is directed by vascular phenotype, vessel stabilization and maturation in malignant melanoma.J Exp Med. 2010; 207: 491-503
- Tumor cells disseminate early but immunosurveillance limits metastatic outgrowth in a mouse model of melanoma.J Clin Invest. 2010; 120: 2030-2039
- The role of genetic variation near interferon-kappa in systemic lupus erythematosus.J Biomed Biotechnol. 2010; : 706825
- Pathway discovery in mantle cell lymphoma by integrated analysis of high resolution gene expression and copy number profiling.Blood. 2010; 116: 953-961
- Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis.J Allergy Clin Immunol. 1999; 103: 1213-1214
- c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.PLoS One. 2010; 5: e10279
- Vam10p defines a Sec18p-independent step of priming which allows yeast vacuole tethering.Proc Natl Acad Sci USA. 2003; 100: 6398-6403
- Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ret transgenic mouse lines.Oncogene. 1999; 18: 837-842
- Effects of light smoking on extra-high-frequency auditory thresholds in young adults.Toxicol Ind Health. 2011; 27: 143-147
- Metastasizing melanoma formation caused by expression of activated N-rasQ61K on an INK4a-deficient background.Cancer Res. 2005; 65: 4005-4011
- BrafV600E cooperates with Pten loss to induce metastatic melanoma.Nat Genet. 2009; 41: 544-552
- Report.Mouse News Lett. 1962; 27: 31
- Novel hairless RET-transgenic mouse line with melanocytic nevi and anagen hair follicles.J Invest Dermatol. 2006; 126: 2547-2550
- Human NDR kinases are rapidly activated by MOB proteins through recruitment to the plasma membrane and phosphorylation.Mol Cell Biol. 2005; 25: 8259-8272
- Mutual dependence of Mob1 and the chromosomal passenger complex for localization during mitosis.Mol Biol Cell. 2010; 21: 380-392
- MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation.Curr Biol. 2008; 18: 311-321
- The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naïve T cells.Proc Natl Acad Sci USA. 2008; 105: 20321-20326
- Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model.Life Sci. 2002; 70: 791-798
- Integrin expression in human melanoma cells with differing invasive and metastatic properties.Clin Exp Metastasis. 1992; 10: 111-120
Article info
Publication history
Published online: December 15, 2011
Accepted:
October 19,
2011
Received in revised form:
October 11,
2011
Received:
June 13,
2011
Identification
Copyright
© 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Inc. All rights reserved.
